Are there any arrangements related to Robert J. Spiegel’s appointment to Ernexa’s (ERNA) board?

Ernexa states that there are no arrangements or understandings between Robert J. Spiegel, M.D. and any other person under which he was appointed as a director of the company.

Are there related-party transactions between Ernexa (ERNA) and Robert J. Spiegel?

Ernexa states there are no transactions between the company and Robert J. Spiegel, M.D. that are reportable under Item 404(a) of Regulation S-K.

Ernexa Therapeutics adds Robert J. Spiegel to board

Q: What board change did Ernexa Therapeutics Inc. (ERNA) announce?

Ernexa Therapeutics Inc. announced that Robert J. Spiegel, M.D. has been appointed to its board of directors, effective September 14, 2026, to serve until his successor is duly elected and qualified or until his earlier death, resignation, or removal.

Q: How will the new Ernexa (ERNA) director Robert J. Spiegel be compensated?

Robert J. Spiegel, M.D. will be compensated under Ernexa’s Board of Directors Compensation Plan, which became effective August 15, 2026 and is described in Ernexa’s Form 10-Q for the period ended June 30, 2026.

Q: Does Ernexa (ERNA) report any family relationships involving Robert J. Spiegel?

Ernexa reports that there is no family relationship between Robert J. Spiegel, M.D. and any director, executive officer, or person nominated or chosen by the company to become a director or executive officer.

Q: What securities of Ernexa (ERNA) are listed on Nasdaq?

Ernexa lists its Common Stock, par value $0.005 per share, under the symbol ERNA, and its Common Stock Purchase Warrants under the symbol ERNAW, both on The Nasdaq Stock Market LLC.

Ernexa Therapeutics appoints Robert J. Spiegel, M.D. to its board of directors with standard board compensation and no related-party relationships disclosed.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. (ERNA) reports that its board of directors has appointed Robert J. Spiegel, M.D. as a director, effective September 14, 2026. He will serve until a successor is duly elected and qualified or until earlier death, resignation, or removal.

Dr. Spiegel will be compensated under Ernexa’s Board of Directors Compensation Plan that became effective August 15, 2026 and is described in the company’s Form 10-Q for the quarter ended June 30, 2026. The company states there are no appointment-related arrangements, no family relationships with current leadership, and no related-party transactions with Dr. Spiegel that are reportable under Item 404(a) of Regulation S-K.

Insights

Analyzing...

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Par value per share: $0.005 per share Board appointment effective date: September 14, 2026 Board compensation plan effective date: August 15, 2026

3 metrics

Par value per share $0.005 per share Par value of Ernexa Therapeutics Inc. common stock

Board appointment effective date September 14, 2026 Effective date of Robert J. Spiegel, M.D. joining the board

Board compensation plan effective date August 15, 2026 Effective date of Ernexa’s Board of Directors Compensation Plan

Key Terms

Nominating and Corporate Governance Committee, Item 404(a) of Regulation S-K, Board of Directors Compensation Plan, Common Stock Purchase Warrants

4 terms

Nominating and Corporate Governance Committee regulatory

"upon the recommendation of the Nominating and Corporate Governance Committee of the board"

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

Item 404(a) of Regulation S-K regulatory

"no transactions between the Company and Dr. Spiegel that are reportable pursuant to Item 404(a) of Regulation S-K"

Board of Directors Compensation Plan financial

"compensated in accordance with the Company’s Board of Directors Compensation Plan adopted effective August 15, 2026"

Common Stock Purchase Warrants financial

"Common Stock Purchase Warrants | | ERNAW | | The Nasdaq Stock Market LLC"

Common stock purchase warrants are tradable instruments that give the holder the right to buy a company’s common shares at a set price before a specified date, like a coupon that lets you purchase stock later at a fixed rate. They matter to investors because they offer a way to gain future upside if the stock rises, but when exercised they increase the number of shares outstanding and can reduce existing shareholders’ ownership and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Ernexa Therapeutics Inc. (ERNA) announce?

Ernexa Therapeutics Inc. announced that Robert J. Spiegel, M.D. has been appointed to its board of directors, effective September 14, 2026, to serve until his successor is duly elected and qualified or until his earlier death, resignation, or removal.

How will the new Ernexa (ERNA) director Robert J. Spiegel be compensated?

Robert J. Spiegel, M.D. will be compensated under Ernexa’s Board of Directors Compensation Plan, which became effective August 15, 2026 and is described in Ernexa’s Form 10-Q for the period ended June 30, 2026.

Does Ernexa (ERNA) report any family relationships involving Robert J. Spiegel?

Ernexa reports that there is no family relationship between Robert J. Spiegel, M.D. and any director, executive officer, or person nominated or chosen by the company to become a director or executive officer.

What securities of Ernexa (ERNA) are listed on Nasdaq?

Ernexa lists its Common Stock, par value $0.005 per share, under the symbol ERNA, and its Common Stock Purchase Warrants under the symbol ERNAW, both on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/16/2026 - 04:51 PM EDT Accepted by SEC EDGAR 09/16/2026 - 04:50 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 14, 2026

Ernexa Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-11460

31-1103425

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1035 Cambridge Street, Suite 18A
Cambridge, MA		02141
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 798-6700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, par value $0.005 per share	ERNA	The Nasdaq Stock Market LLC
Common Stock Purchase Warrants	ERNAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 14, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the “Board”) of Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”) approved the appointment of Robert J. Spiegel, M.D. to serve as a member of the Board, effective immediately. Dr. Spiegel will serve until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.

Dr. Spiegel will be compensated in accordance with the Company’s Board of Directors Compensation Plan adopted effective August 15, 2026, as described in our Quarterly Report on Form 10-Q for the period ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026.

There are no arrangements or understandings between Dr. Spiegel and any other person or persons pursuant to which Dr. Spiegel was appointed as a director of the Company, and there is no family relationship between Dr. Spiegel and any other director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer. There are no transactions between the Company and Dr. Spiegel that are reportable pursuant to Item 404(a) of Regulation S-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Ernexa Therapeutics Inc.

Dated: September 16, 2026	By:	/s/ Sanjeev Luther
		Sanjeev Luther
		President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents